BioSpace News Archive

Through a revolving credit facility, SFS purchases the debt from Siemens on behalf of the customer and then gives the customer flexible repayment options with a choice of when to pay, up to 180 days.

SkinBioTherapeutics has appointed Stuart Ashman as an executive director, effective from April 18th.. Stuart will succeed Professor Cath O’Neill as CEO after a period of transition, which will enable him to gain an understanding of the science based company which is focused on skin health

NeuroSigma, Inc., a Los Angeles-based bioelectronics company focused on commercializing Trigeminal Nerve Stimulation technology for treating neurological and neuropsychiatric disorders announced that its Monarch® eTNS® System received FDA clearance as a non-drug treatment for attention deficit hyperactivity disorder.